CRISPR Therapeutics (CRSP) net assets (shareholders' equity)

Net assets · fiscal 2025
$1.92B

CRISPR Therapeutics (CRSP) had net assets of $1.92B at the end of fiscal 2025 (December 31, 2025). That is 0.5% lower than the $1.93B of fiscal 2024. Figures as of 19 Nov 2026, 03:35 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Net assets, fiscal 2025
$1.92B
Change on fiscal 2024
−0.5%
Growth, 5 years
+2.9% a year
Highest on record
$2.40Bfiscal 2021
Lowest on record
-$29.10Mfiscal 2015
Fiscal years on record
122014–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics net assets (shareholders' equity), in more detail

Over the five fiscal years to 2025 net assets grew at a compound 2.9% a year. Across the 12 fiscal years on record (2014–2025), the highest was $2.40B in fiscal 2021 and the lowest -$29.10M in fiscal 2015.

History · 12 fiscal years

Net assets by fiscal year

CRISPR Therapeutics net assets (shareholders' equity), year by year

CRISPR Therapeutics (CRSP) net assets (shareholders' equity) by fiscal year
Fiscal yearNet assetsChangeYear ended
2025$1.92B 0.5% down
2024$1.93B 2.6% up
2023$1.88B 0.4% up
2022$1.88B 21.8% down
2021$2.40B 44.2% up
2020$1.66B 77.2% up
2019$939.43M 139.5% up
2018$392.20M 108.8% up
2017$187.83M 19.3% down
2016$232.85M—
2015-$29.10M—
2014-$6.97M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value.

How to read it

Large buybacks and write-offs shrink it without the business getting worse, so a falling or negative figure needs the reason before a verdict.

Net assets at health care companies of similar size

Net assets of CRISPR Therapeutics and comparable companies
CompanyNet assetsFiscal year
Heartflow HTFL$300.65M2025
CRISPR Therapeutics CRSP$1.92B2025
Travere Therapeutics TVTX$114.83M2025
Option Care Health OPCH$1.33B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics net assets (shareholders' equity): questions and answers

What are CRISPR Therapeutics's net assets?

CRISPR Therapeutics (CRSP) had net assets of $1.92B at the end of fiscal 2025 (December 31, 2025). That is 0.5% lower than the $1.93B of fiscal 2024.

What is the growth rate of CRISPR Therapeutics's net assets?

Over the five fiscal years to 2025 net assets grew at a compound 2.9% a year.

What are the highest and lowest net assets figures on record for CRISPR Therapeutics?

Across the 12 fiscal years on record (2014–2025), the highest was $2.40B in fiscal 2021 and the lowest -$29.10M in fiscal 2015.

How is CRISPR Therapeutics's net assets calculated?

Net assets is shareholders' equity on the balance sheet at the fiscal year-end: total assets minus total liabilities, also called book value. For CRISPR Therapeutics it is on record here for 12 fiscal years, 2014 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) net assets (shareholders' equity)”, data as of 19 November 2026. https://funkfolio.com/stock/CRSP/net-assets

Underlying data: the company's filings with the SEC and Yahoo Finance.